DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION – Trademark Portfolio

Entity Type: 99

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include D.A.R.E.. The owner is based in LOS ANGELES, CA.

760 WESTWOOD PLAZA

LOS ANGELES, CA 90024

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

D.A.R.E.
D.A.R.E.
Registered 1970

Trademark Classifications

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION have?

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION file in?

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION's most well-known trademarks?

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION's registered trademark portfolio includes well-known marks such as D.A.R.E.. These are among 1 currently registered trademark in the portfolio.

What is DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION's trademark registration success rate?

DRUG ABUSE RESEARCH AND EDUCATION FOUNDATION has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.